[{"id":"0300bd11-3c88-4727-a08a-0abd664e0d55","acronym":"","url":"https://clinicaltrials.gov/study/NCT05773326","created_at":"2023-03-17T14:02:34.285Z","updated_at":"2024-07-02T16:35:02.449Z","phase":"Phase 1","brief_title":"Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG","source_id_and_acronym":"NCT05773326","lead_sponsor":"Nader Sanai","biomarkers":" PIK3CA • PTEN • mTOR • PIK3R1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation","tags":["PIK3CA • PTEN • mTOR • PIK3R1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2024-05-21"},{"id":"d7d6598c-31e5-4bc3-b406-5e9ff144fe1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03834740","created_at":"2021-01-18T18:56:01.539Z","updated_at":"2024-07-02T16:35:04.374Z","phase":"Phase 1","brief_title":"A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection","source_id_and_acronym":"NCT03834740","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression","tags":["PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 02/18/2022","study_completion_date":" 02/18/2022","last_update_posted":"2024-05-10"},{"id":"afe413d7-7e85-457e-9af3-9c556a34d9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT01396408","created_at":"2021-01-18T05:44:09.814Z","updated_at":"2024-07-02T16:35:17.762Z","phase":"Phase 2","brief_title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT01396408","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PTEN • STK11 • NF1","pipe":" | ","alterations":" EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification","tags":["PTEN • STK11 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • temsirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 02/09/2012","start_date":" 02/09/2012","primary_txt":" Primary completion: 07/06/2015","primary_completion_date":" 07/06/2015","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"ea259fb5-3f93-4045-aa2d-a83218c93202","acronym":"","url":"https://clinicaltrials.gov/study/NCT01141309","created_at":"2021-01-18T04:32:19.305Z","updated_at":"2024-07-02T16:35:42.533Z","phase":"Phase 2","brief_title":"Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer","source_id_and_acronym":"NCT01141309","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PTEN • TG","pipe":" | ","alterations":" PTEN mutation • MTOR mutation","tags":["PTEN • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-19"},{"id":"794a4f22-30c9-49fc-add3-aa5bcabfe05f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05331326","created_at":"2022-04-15T11:53:19.863Z","updated_at":"2024-07-02T16:36:12.316Z","phase":"Phase 2","brief_title":"A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway","source_id_and_acronym":"NCT05331326","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • MTOR mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2022-04-15"},{"id":"a041e75d-dea4-42aa-90f8-c25cae180d4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05054166","created_at":"2021-09-23T17:52:59.544Z","updated_at":"2024-07-02T16:36:24.082Z","phase":"","brief_title":"Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study","source_id_and_acronym":"NCT05054166","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" HER-2 • mTOR • PI3K","pipe":" | ","alterations":" HER-2 negative • MTOR mutation","tags":["HER-2 • mTOR • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/30/2021","study_completion_date":" 08/30/2021","last_update_posted":"2021-09-23"},{"id":"859d4daf-1a31-438b-8dbf-f8ed4a89b5e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02357836","created_at":"2021-05-03T19:53:14.312Z","updated_at":"2024-07-02T16:36:30.803Z","phase":"Phase 1","brief_title":"Neoadjuvant Itraconazole in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02357836","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" CCND1 • PTCH1 • HIF1A • CD34 • GLI1 • CASP3 • CD31 • GLI2 • PECAM1","pipe":" | ","alterations":" MTOR mutation","tags":["CCND1 • PTCH1 • HIF1A • CD34 • GLI1 • CASP3 • CD31 • GLI2 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2021-05-03"},{"id":"c6482f62-b29d-422c-ac88-2950e4e5187d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00827359","created_at":"2021-01-18T03:08:51.503Z","updated_at":"2025-02-25T15:49:51.116Z","phase":"Phase 2","brief_title":"Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT00827359","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" mTOR • PI3K","pipe":" | ","alterations":" MTOR mutation","tags":["mTOR • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2021-02-24"},{"id":"9e574470-b55c-4fb9-ba76-d1930189d237","acronym":"KCSG-BR18-13","url":"https://clinicaltrials.gov/study/NCT03698383","created_at":"2021-01-18T18:07:34.589Z","updated_at":"2024-07-02T16:36:34.376Z","phase":"Phase 2","brief_title":"Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT03698383 - KCSG-BR18-13","lead_sponsor":"Korean Cancer Study Group","biomarkers":" PIK3CA • PTEN • mTOR","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation • MTOR mutation","tags":["PIK3CA • PTEN • mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gedatolisib (PF-05212384) • Herzuma (trastuzumab-pkrb)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/03/2019","start_date":" 12/03/2019","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-02-18"},{"id":"3ff6a5b1-214e-4af5-a89e-ebcc5422b1b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04736589","created_at":"2021-02-03T16:02:10.745Z","updated_at":"2024-07-02T16:36:35.121Z","phase":"Phase 3","brief_title":"Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway","source_id_and_acronym":"NCT04736589","lead_sponsor":"Peking Union Medical College","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • MTOR mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Irene (pyrotinib) • sirolimus • Cipterbin (inetetamab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2027","study_completion_date":" 02/02/2027","last_update_posted":"2021-02-03"}]